Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants-Reference-Cited by-同舟云学术

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants

Published:2023-08-04 Issue:1 Volume:8 Page:
ISSN:2059-0105
Container-title:npj Vaccines
language:en
Short-container-title:npj Vaccines

Author:

Springer David N.^ORCID,Bauer Michael,Medits Iris^ORCID,Camp Jeremy V.^ORCID,Aberle Stephan W.,Burtscher Clemens,Höltl Eva,Weseslindtner Lukas,Stiasny Karin^ORCID,Aberle Judith H.^ORCID

Abstract

AbstractWe report SARS-CoV-2 neutralizing antibody titers in sera of triple-vaccinated individuals who received a booster dose of an original monovalent or a bivalent BA.1- or BA.4/BA.5-adapted vaccine or had a breakthrough infection with Omicron variants BA.1, BA.2 or BA.4/BA.5. A bivalent BA.4/BA.5 booster or Omicron-breakthrough infection induced increased Omicron-neutralization titers compared with the monovalent booster. The XBB.1.5 variant effectively evaded neutralizing-antibody responses elicited by current vaccines and/or infection with previous variants.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Infectious Diseases,Pharmacology,Immunology

Link

https://www.nature.com/articles/s41541-023-00708-9.pdf

Reference18 articles.

1. Barouch, D. H. Covid-19 vaccines—immunity, variants, boosters. N. Engl. J. Med. 387, 1011–1020 (2022).

2. Medits, I. et al. Different neutralization profiles after primary SARS-CoV-2 Omicron BA.1 and BA.2 infections. Front. Immunol. 13, 946318 (2022).

3. Lin, D. Y. et al. Effectiveness of bivalent boosters against severe Omicron infection. N. Engl. J. Med. 388, 764–766 (2023).

4. Link-Gelles R, C. A. et al. Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection—Increasing Community Access to Testing Program, United States, September–November 2022. MMWR Morb. Mortal. Wkly. Rep. 71, 1526–1530 (2022).

5. Addetia, A. et al. Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants. Preprint at bioRxiv https://doi.org/10.1101/2023.01.17.523798 (2023).

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants;Journal of Infection;2024-10

2. Beyond COVID-19: the promise of next-generation coronavirus vaccines;npj Viruses;2024-08-22

3. Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants;Emerging Microbes & Infections;2024-08-19

4. Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity;Heliyon;2024-08

5. Repeated Omicron infection dampens immune imprinting from previous vaccination and induces broad neutralizing antibodies against Omicron sub-variants;Journal of Infection;2024-08